Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945444 | 1.00 | SLC7A5 (0.48) | SLC7A5CA12CA1CA2CA4 | |
| SCHEMBL13396369 | 0.99 | SLC7A5 (0.47) | SLC7A5CA12CA1CA2CA4 | |
| SCHEMBL13396364 | 0.97 | SLC7A5 (0.48) | SLC7A5CA12CA1CA2CA4 | |
| SCHEMBL13396373 | 0.88 | SLC7A5 (0.47) | SLC7A5PTGS2MMP2ALDH1A1HDAC8 | |
| SCHEMBL3310196 | 0.88 | PTGS2 (0.49) | SLC7A5CA12CA1CA2CA4 | |
| SCHEMBL3310195 | 0.88 | PTGS2 (0.49) | SLC7A5CA12CA1CA2CA4 | |
| SCHEMBL13396367 | 0.86 | SLC7A5 (0.44) | SLC7A5PTGS2MMP2ALDH1A1HDAC8 | |
| SCHEMBL16607621 | 0.86 | SLC7A5 (0.59) | SLC7A5HDAC8ITGB3ITGA2B | |
| SCHEMBL28758664 | 0.85 | PTGS1 (0.47) | SLC7A5CA12CA1CA2CA4 | |
| SCHEMBL13396389 | 0.85 | PTGS2 (0.41) | SLC7A5CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102186873-A | New no-releasing steroids for the treatment of retina and macula lutea diseases | NICOX SA | 2011-09-14 | — | — | CN | disclosed |
| US-20110130375-A1 | NEW NO-RELEASING STEROIDS FOR THE TREATMENT OF RETINA AND MACULA LUTEA DISEASES | NICOX S.A. (FR) | 2011-06-02 | — | — | US | disclosed |
| US-20110130375-A1 | NEW NO-RELEASING STEROIDS FOR THE TREATMENT OF RETINA AND MACULA LUTEA DISEASES | NICOX S.A. (FR) | 2011-06-02 | — | — | US | disclosed |
| EP-2321333-A1 | NEW NO-RELEASING STEROIDS FOR THE TREATMENT OF RETINA AND MACULA LUTEA DISEASES | Nicox S.A. (FR) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010015528-A1 | NEW NO-RELEASING STEROIDS FOR THE TREATMENT OF RETINA AND MACULA LUTEA DISEASES | NICOX S.A. (FR) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130375-A1 | NEW NO-RELEASING STEROIDS FOR THE TREATMENT OF RETINA AND MACULA LUTEA DISEASES | LHCGR, NR5A1, LSS | SLC7A5 868/4885CA12 4141/4885CA1 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.